Published in AIDS Weekly, January 23rd, 2006
IMNR's HIV products are based on its patented whole inactivated virus technology, co-invented by company founder Dr. Jonas Salk to stimulate HIV immune responses. Remune, currently in phase 2 clinical trials, is being developed as a first-line treatment for people with early-stage HIV.
IMNR also developing an immune-based therapy for MS, NeuroVax, which is currently in phase 2 clinical trials.
The OTC Bulletin Board (OTCBB) is a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.